Internal Medicine

Medicine & Life Sciences

1. Acute Myeloid Leukemia 14%
2. Adenocarcinoma 19%
3. Adenoma 13%
4. Alaska Natives 13%
5. Anaplastic Thyroid Carcinoma 12%
6. Anthracyclines 14%
7. Aromatase Inhibitors 18%
8. B-Cell Chronic Lymphocytic Leukemia 26%
9. Barrett Esophagus 41%
10. Biomarkers 18%
11. Biopsy 26%
12. Bortezomib 18%
13. Breast Neoplasms 100%
14. Cardiomyopathies 16%
15. Cholangiocarcinoma 29%
16. Clinical Trials 21%
17. Colon 12%
18. Colonoscopy 23%
19. Colorectal Neoplasms 17%
20. Confidence Intervals 30%
21. Coronavirus 16%
22. Cyclophosphamide 13%
23. Databases 12%
24. Dexamethasone 17%
25. Dilated Cardiomyopathy 14%
26. Drug Therapy 40%
27. Endoscopic Mucosal Resection 12%
28. Endoscopic Ultrasound-Guided Fine Needle Aspiration 14%
29. Endoscopy 30%
30. Extracellular Vesicles 15%
31. Fibrosis 14%
32. Fine Needle Biopsy 13%
33. Gastric Emptying 23%
34. Gastroparesis 37%
35. Genes 22%
36. Growth 13%
37. Guidelines 19%
38. Heart 15%
39. Heart Failure 17%
40. Hepatocellular Carcinoma 18%
41. human ERBB2 protein 21%
42. Immunotherapy 13%
43. Incidence 18%
44. Interstitial Cells of Cajal 40%
45. Irritable Bowel Syndrome 30%
46. Kidney 14%
47. Kinesin 13%
48. Lasers 13%
49. Lenalidomide 23%
50. Letrozole 15%
51. Liver 16%
52. Liver Transplantation 35%
53. Lung 13%
54. Lymphoma 14%
55. Melanoma 22%
56. Meta-Analysis 23%
57. Mortality 27%
58. Multicenter Studies 15%
59. Multiple Myeloma 54%
60. Mutation 22%
61. Myocarditis 49%
62. Myotomy 14%
63. Neoplasm Metastasis 14%
64. Neoplasms 96%
65. Non-Small Cell Lung Carcinoma 16%
66. Odds Ratio 14%
67. Paclitaxel 21%
68. Pancreatic Neoplasms 23%
69. PCI 32765 13%
70. pembrolizumab 14%
71. Pharmaceutical Preparations 16%
72. Placebos 18%
73. Polyps 22%
74. Population 19%
75. Progression-Free Survival 22%
76. Prostatic Neoplasms 21%
77. Proteins 15%
78. Pulmonary Arterial Hypertension 17%
79. Quality of Life 14%
80. Recurrence 26%
81. Registries 16%
82. Renal Cell Carcinoma 18%
83. Rituximab 15%
84. Safety 32%
85. Serum 17%
86. Smooth Muscle 13%
87. Stomach 29%
88. Survival 58%
89. Systematic Reviews 24%
90. T-Lymphocytes 18%
91. taxane 13%
92. Technology 12%
93. Therapeutics 79%
94. Thyroid Gland 13%
95. Transplant Recipients 13%
96. Transplantation 12%
97. Transplants 26%
98. Trastuzumab 38%
99. Waldenstrom Macroglobulinemia 16%